AMP

AMP president updates CDC committee on H1N1 testing

Atlanta, GA -- September 2-3, 2009 -- Dr. Jan Nowak, President of the Association for Molecular Pathology presented public comments today at the Clinical Laboratory Improvement Advisory Committee meeting.

M. D. Anderson study finds common diabetic therapy reduces risk of pancreatic cancer

HOUSTON - Taking the most commonly-prescribed anti-diabetic drug, metformin, reduces an individual's risk of developing pancreatic cancer by 62 percent, according to research from The University of Texas M. D. Anderson Cancer Center, published in the Aug. 1 issue of Gastroenterology.

Second gene linked to familial testicular cancer

Specific variations or mutations in a particular can gene raise a man's risk of familial, or inherited, testicular germ-cell cancer, the most common form of this disease, according to new research by scientists at the National Institutes of Health.

Association for Molecular Pathology comments to the SACGHS

Washington, DC -- June 12, 2009 -- In public comments given today before the Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society (SACGHS), the Association for Molecular Pathology (AMP) addressed three areas: Comparative Effectiveness Research (CER), evidence for coverage of genetic and genomic tests, and gene patents.

AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research

Washington, DC -- June 12, 2009 -- The Association for Molecular Pathology (AMP) today released the text of a comment letter it has provided to the Federal Coordinating Council for Comparative Effectiveness Research (CER) in which AMP sets forth its recommendations for priority areas on which to focus CER activities.

Association for Molecular Pathology Comments to SACGHS

In pubic comments given today before the Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society (SACGHS), the Association for Molecular Pathology (AMP) addressed three areas: Comparative Effectiveness Research (CER), evidence for coverage of genetic and genomic tests, and gene patents.